Table 1.
Patients and samples used for the study.
| Omicron |
Delta |
|||||||
|---|---|---|---|---|---|---|---|---|
| Total Patients | 1119 |
908 |
||||||
| Fully Vaccinated | With booster dose | Unvaccinated | Partially vaccinated | Fully Vaccinated | With booster dose | Unvaccinated | Partially vaccinated | |
| Patients(%) | 521 (46.6) | 183 (16.4) | 380 (33.96) | 35 (3.1) | 262 (28.9) | 63 (6.9) | 561 (61.8) | 22 (2.4) |
| Ct analysis(%) | 177 (33.97) | 52 (28.4) | 166 (43.7) | 17 (48.6) | 189 (72.1) | 41 (65.1) | 400 (71.3) | 12 (54.5) |
| Patients with known days from the onset of symptoms(%) | 154 (29.6) | 53 (28.96) | 135 (35.5) | 14 (40) | 105 (40.1) | 15 (23.8) | 222 (39.6) | 9 (40.9) |
| IgG(%) | 148 (28.4) | 45 (24.6) | 0 | 13 (37.1) | 176 (67.2) | 40 (63.5) | 0 | 10 (45.5) |
| Cell culture (total)(%) | 54 (10.4) | 77 (42.1) | 83 (21.8) | 5(14.3) | 55 (21) | 42 (66.7) | 56 (9.98) | 0 |
| Cell culture (Ct < 20) (%) | 45 (8.6) | 34 (18.6) | 51 (13.4) | 4 (11.4) | 51 (19.5) | 23 (36.5) | 39 (9.95) | 0 |
Full vaccination was based on the CDC definition of positive test results more than 14 days post the second shot for pfizer/BioNTech BNT162b2 and Moderna mRNA-1273 or 14 days after the J&J/Janssen, but no booster doses
Partially vaccinated include patients who received only one shot for pfizer/BioNTech BNT162b2 or Moderna mRNA-1273.